Wegovy vs Zepbound

If you’ve decided you want a prescription weight-loss medication and you’re choosing between brands, the realistic choice in 2026 is Wegovy or Zepbound. These are the two drugs the FDA has approved specifically for chronic weight management — not Ozempic or Mounjaro, which are the diabetes-labeled versions of the same two molecules. Picking between them isn’t really a question of which is “best” in the abstract. It’s a question of which one fits your health profile, your insurance, and the way you want to take it.

This page is the brand-level decision. The deeper science of how the two molecules differ, and the narrow “which loses more weight” ranking, live on their own pages — here the focus is the practical fork: which brand do you actually walk away with, and why.

Same goal, two different molecules

Wegovy is semaglutide, made by Novo Nordisk. It activates a single receptor, GLP-1, which curbs appetite, slows stomach emptying, and quiets “food noise.” Zepbound is tirzepatide, made by Eli Lilly. It activates two receptors — GLP-1 and GIP — and that dual action is the leading explanation for why it tends to produce larger weight loss on average.

Both are once-weekly subcutaneous injections (Wegovy also now comes as a daily pill — more on that below). Both are adjuncts to diet and physical activity, not standalone fixes. Both share the same boxed warning about thyroid C-cell tumors and are contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2. The molecule-level mechanism comparison is its own topic; what matters at the brand-choice level is that these are genuinely different drugs, not two doses of the same thing.

What each brand is actually approved for

This is the factor most “which is stronger” comparisons skip, and it’s often the one that decides the brand. Wegovy and Zepbound carry different secondary FDA indications, and those indications frequently determine whether insurance pays.

Wegovy (semaglutide) is approved for:

• Chronic weight management in adults, and in adolescents aged 12 and older — it’s the brand to use when a teenager needs treatment, because Zepbound is adults-only.
• Reducing the risk of major cardiovascular events (heart attack, stroke) in adults with established cardiovascular disease who are overweight or obese — the first weight-management drug to earn a cardiovascular indication.
• A liver indication for MASH (metabolic dysfunction-associated steatohepatitis), added in 2025.

Zepbound (tirzepatide) is approved for:

• Chronic weight management in adults.
• Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first drug ever approved for OSA, added at the end of 2024.

Why this matters: if you have established heart disease, Wegovy’s cardiovascular indication can be a coverage door that pure weight-loss use doesn’t open. If you have diagnosed moderate-to-severe sleep apnea, Zepbound’s OSA indication can be that door instead. These aren’t boxes to engineer onto your record — they’re genuine medical routes for people who already qualify. But knowing which condition you actually have can point straight to the brand your plan is most likely to cover.

Note: A secondary indication only helps if it’s a real diagnosis documented by your clinician. Don’t go looking for a comorbidity to “unlock” a drug — that’s a conversation for an honest medical evaluation, not a workaround.

Efficacy: what the head-to-head actually showed

For years, Wegovy and Zepbound were compared only through separate trials with different participants — useful but imperfect. That changed with SURMOUNT-5, the first direct head-to-head, which randomized 751 adults with obesity (no diabetes) to maximum tolerated doses of each drug for 72 weeks.

The result: Zepbound produced about 20% average weight loss versus about 14% for Wegovy — roughly 50 versus 33 pounds on average. Zepbound also beat Wegovy on every secondary target, with about 32% of Zepbound users losing at least a quarter of their body weight compared with about 16% on Wegovy.

Two honest caveats keep this from being the whole story. First, these are averages across a wide spread — plenty of people lose more or less than the mean, and some respond exceptionally well to semaglutide. Second, the gap is narrowing: a higher-dose Wegovy (7.2 mg, approved March 2026) pushes semaglutide’s average upward, closing part of the distance the older 2.4 mg dose left open. If you want the efficacy question dissected on its own — trial design, the dose ceilings, the real-world numbers that run lower than trial figures — that’s covered in depth on the dedicated weight-loss comparison. For brand-choice purposes, the takeaway is simple: Zepbound has the efficiency edge on paper, but it’s a margin, not a chasm, and it isn’t the only thing worth weighing.

Formulation: pill, pen, or vial

How you take the drug is a real differentiator, and it breaks cleanly by brand.

Wegovy offers the most format flexibility. There’s the familiar single-dose injector pen, and there’s now a daily oral tablet — the only option here that doesn’t involve a needle. The pill has to be taken on an empty stomach with specific timing rules, so it trades injection-avoidance for a daily routine, but for needle-averse patients it’s a genuine alternative.

Zepbound is injection-only, but it comes in two delivery forms that matter for cost and access: the KwikPen auto-injector and lower-cost single-dose vials (which require drawing the dose with a syringe). The vial route is cheaper but involves more handling; the pen is simpler but pricier.

This formulation split feeds directly into coverage and cost, because — as you’ll see — some payment programs cover only specific formats.

What you’ll actually pay

Sticker prices for both brands once ran past $1,000 a month, but in 2026 that’s rarely what people pay. Both manufacturers now run direct cash-pay programs that collapsed those figures dramatically.

Roughly speaking, Novo Nordisk’s direct program prices Wegovy in the low-to-mid hundreds per month, with the oral pill’s starting tier among the cheapest legitimate branded options. Lilly’s direct program prices Zepbound’s single-dose vials in a similar band by dose, with the KwikPen costing more. Exact numbers shift with promotions and dose, so treat any specific figure as a snapshot rather than a fixed rate — the detailed, current pricing lives on the per-brand cost pages.

The practical point at the brand level: cash-pay pricing has narrowed the gap between the two brands so much that price alone rarely decides it anymore. Manufacturer savings cards exist too, but they generally require commercial insurance and exclude government plans. And one route that used to be the cheap option — broadly compounded versions of these drugs — has largely closed, after the FDA’s shortage-driven compounding window wound down in 2025 and a narrow patient-specific exception is all that remains. Cheap compounded “semaglutide” or “tirzepatide” from a telehealth vendor is no longer the simple discount it once looked like.

Insurance and Medicare

Commercial coverage for weight loss is shrinking and increasingly gated behind prior authorization, BMI thresholds, and documented prior attempts. Whether your specific plan favors Wegovy or Zepbound often comes down to formulary placement and which secondary indication you have — which loops back to the indication section above.

Medicare is its own situation. Standard Part D is statutorily barred from covering either drug for weight loss alone. The temporary Medicare GLP-1 Bridge, running from July 2026 through 2027, fills part of that gap: eligible Part D enrollees can get covered weight-loss GLP-1s for a flat $50 monthly copay, with eligibility gated on BMI. Here the formulation fork bites — the Bridge covers all formulations of Wegovy (injection and tablet) but only the KwikPen formulation of Zepbound, not its vials or single-dose pens. If you’re a Medicare beneficiary leaning toward Zepbound for weight loss, that detail can steer both your brand and your format. (Coverage mechanics, prior-auth steps, and the Bridge’s fine print are detailed on the insurance page.)

Tolerability and switching

Side-effect profiles are broadly similar: mostly gastrointestinal — nausea, diarrhea, constipation — concentrated during the gradual dose increases each drug requires. Neither is clearly “gentler” for everyone; tolerability is individual, and the dose you’re ramped to matters as much as the molecule.

People do switch between the brands, most often after a plateau on Wegovy or because coverage changed. Switching is a clinician-managed decision, not a self-directed swap: there’s no clean dose-for-dose conversion between semaglutide and tirzepatide, so a prescriber restarts titration appropriately for the new drug. The wrong way to switch is to carry a number over from one to the other on your own.

How to actually choose

Strip away the marketing and the decision usually comes down to a short set of honest questions:

• Do you have a qualifying secondary condition? Established cardiovascular disease points toward Wegovy; moderate-to-severe sleep apnea points toward Zepbound — both because of genuine indications and the coverage they can unlock.
• Is the patient under 18? Wegovy is the only one approved down to age 12.
• Do you want to avoid injections? Only Wegovy offers a pill.
• What does your coverage favor? Check your formulary and your secondary diagnosis before assuming the “stronger” drug is the cheaper or covered one.
• Are you on Medicare? The Bridge’s formulation rules may decide your brand and format for you.
• All else equal, do you want the highest average weight loss? That’s Zepbound — with the caveat that “average” isn’t “guaranteed,” and the brand you can stay on consistently beats the one you can’t.

The best brand is the one you and a legitimate prescriber can match to your health, your access, and your ability to stay on it month after month. A few percentage points of trial-average difference matter far less than picking something you’ll actually keep using — and that you’re being evaluated for properly, not handed from a website.

This page is educational and not medical advice. Drug approvals, prices, and coverage rules in this space change quickly; the details here reflect the situation as of the date above and should be confirmed with a licensed provider for your specific case.